| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2019: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2017: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
|---|
| Outline of Final Research Achievements |
VHL disease is a hereditary cancer syndrome and patients are suffered from various tumors such as RCC. Since there exist no mice model for this disease, we tried to explore new experimental model using patients derived iPS cells. We successfully develop several VHL-/- iPS. Importantly, when we differentiate those cells to renal proximal tubular cells, the tumor origin of RCC, some pathological features of the tumors were recapitulated. Moreover, the expression of tumor markers of RCC was also confirmed.
|
